KIAA1549 is altered in 53.15% of pilocytic astrocytoma patients [3].

KIAA1549 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

KIAA1549 is altered in 10.4% of low grade glioma patients [3].

KIAA1549 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

KIAA1549 is altered in 2.67% of glioma patients [3].

KIAA1549 is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and glioma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIAA1549 is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].

KIAA1549 is an inclusion criterion in 1 clinical trial for optic nerve glioma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and optic nerve glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].